Diabetic Macular Edema

The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo (faricimab-svoa) for wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo targets and inhibits two disease pathways linked to several...

Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME).  Results from year two of KESTREL were consistent with...

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects...

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong...

Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) 2 mg in patients with diabetic macular edema (DME). Two-year (week 100) data of the KITE study...

Adverum Biotechnologies Inc (NASDAQ: ADVM) has decided to drop the development of ADVM-022 intravitreal (IVT) injection gene therapy in diabetic macular edema (DME) after dose-limiting toxicity (DLT) was observed at the high dose (6 x 10^11 vg/eye) in patients with DME.  In...

Rezolute Inc (NASDAQ: RZLT) has announced positive topline results from Phase 1a clinical study evaluating RZ402 to treat diabetic macular edema (DME). Single-dose oral administration of RZ402 resulted in plasma concentrations that substantially exceeded target...

Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year data, 6mg Beovu showed non-inferiority in change in...

Shares of Clearside Biomedical Inc (NASDAQ: CLSD) has 91 percent upside, according to a note from Stifel, which initiated coverage of the stock with a Buy rating and $13 price target. "Clearside has developed a novel ocular injection platform to deliver drug[s] optimally throughout the eye by way...